Have a personal or library account? Click to login
Incidence of pathogens infections in a Romanian Intensive Care Unit and sensitivity to antibiotics. A prospective single center study Cover

Incidence of pathogens infections in a Romanian Intensive Care Unit and sensitivity to antibiotics. A prospective single center study

Open Access
|Feb 2016

References

  1. 1. Sękowska A, Gospodarek E, Kusza K. The prevalence of infections and colonisation with Klebsiella pneumoniae strains isolated in ICU patients. Anaesthesiol Intensive Ther. 2014;46:280-283.10.5603/AIT.2014.0045
  2. 2. Różańska A, Bulanda M. Demographic characteristics of patients and their assessment of selected hygienic practices of hospital personnel in the context of safety climate of hospitalization. Am J Infect Control. 2015;43:354-357.10.1016/j.ajic.2014.12.022
  3. 3. Singh S, Goyal R, Ramesh GS, et al. Control of hospital acquired infections in the ICU: A service perspective. Med Journal Armed Forces India. 2015;71:28-32.10.1016/j.mjafi.2014.08.008
  4. 4. Sevransky JE, Martin GS, Shanholtz C, et al. Mortality in sepsis versus non-sepsis induced acute lung injury. Crit Care. 2009;13:R150.10.1186/cc8048
  5. 5. Coelho FR, Martins JO. Diagnostic methods in sepsis: the need of speed. Rev Assoc Med Bras. 2012;58:498-504.10.1590/S0104-42302012000400024
  6. 6. Singh S, Chaturvedi R, Garg SM, Datta R, Kumar A. Incidence of healthcare associated infection in the surgical ICU of a tertiary care hospital. Med Journal Armed Forces India. 2013;69:124-129.10.1016/j.mjafi.2012.08.028
  7. 7. Dereli N, Ozayar E, Degerli S, Sahin S, Koç F. Three-Year Evaluation of Nosocomial Infection Rates of the ICU. Rev Bras Anestesiol. 2013;63:73-84.10.1016/S0034-7094(13)70199-5
  8. 8. Harwan WA, Abbassi MM, El-Attar MM, Farid SF. Pharmacoeconomic study of antibiotics used in the treatment of lower respiratory tract infections in ICU patients: A case study in an Egyptian hospital. Bull Fac Pharmacy. 2014;52:135-144.10.1016/j.bfopcu.2014.04.001
  9. 9. Scherbaum M, Kösters K, Mürbeth RE, et al. Incidence, pathogens and resistance patterns of nosocomial infections at a rural hospital in Gabon. BMC Infect Dis. 2014;14:124.10.1186/1471-2334-14-124394398724592922
  10. 10. Guggenbichler J, Assadian O, Kramer M. Incidence and clinical implication of nosocomial infections associated with implantable biomaterials - catheters , ventilator-associated pneumonia , urinary tract infections. GMS Krankenhhyg Interdiszip. 2011;6:1-19.
  11. 11. McDonald CI, Fung YL, Shekar K, et al. The impact of acute lung injury, ECMO and transfusion on oxidative stress and plasma selenium levels in an ovine model. J Trace Elem Med Biol. 2015;30:4-10.10.1016/j.jtemb.2015.01.00425744503
  12. 12. Mérens A, Delacour H, Plésiat P, Cavallo J-D, Jeannot K. Pseudomonas aeruginosa et résistance aux antibiotiques. Rev Francoph des Lab. 2011;2011:49-62.10.1016/S1773-035X(11)71102-9
  13. 13. Mahafza T, Batarseh S, Bsoul N. Early vs. late tracheostomy for the ICU patients: Experience in a referral hospital. Saudi J Anaesth. 2012;6:152-154.10.4103/1658-354X.97029338525822754442
  14. 14. Juayang AC, Jr DGM, Reyes GBDL, Acosido MAD, Gallega CT. Review on the Antimicrobial Resistance of Pathogens from Tracheal and Endotracheal Aspirates of Patients with Clinical Manifestations of Pneumonia in Bacolod City in 2013. International Journal of Bacteriology. 2015;2015.10.1155/2015/942509474548026904750
  15. 15. Gupta A, Ampofo K, Rubenstein D, Saiman L. Extended spectrum beta lactamase-producing Klebsiella pneumoniae infections: a review of the literature. J Perinatol. 2003;23:439-443.10.1038/sj.jp.721097313679928
  16. 16. Shigemoto N, Kayama S, Kuwahara R, et al. A novel metallo-β- lactamase, IMP-34, in Klebsiella isolates with decreased resistance to imipenem. Diagn Microbiol Infect Dis. 2013;76:119-121.10.1016/j.diagmicrobio.2013.02.03023541689
  17. 17. Charrouf FO, Hamze M, Mallat H, Achkar M, Dabboussia F. Characterization of resistance genes in 68 ESBL-producing Klebsiella pneumonia in Lebanon. Médecine Mal Infect. 2014;44:535-538.10.1016/j.medmal.2014.10.00125453362
  18. 18. Murray CK, Hospenthal DR. Acinetobacter infection in the ICU. Crit Care Clin. 2008;24:237-248.10.1016/j.ccc.2007.12.00518361943
  19. 19. Vourli S, Frantzeskaki F, Meletiadis J, et al. Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant Acinetobacter baumannii isolated from ICU patients. Int J Antimicrob Agents. 2015;45:670-671.10.1016/j.ijantimicag.2015.02.00525795317
  20. 20. Dueñas Díez AI, Bratos Pérez MA, Eiros Bouza JM, et al. Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin. Int J Antimicrob Agents. 2004;23:487-493.10.1016/j.ijantimicag.2003.09.02615120728
  21. 21. Lesho E, Wortmann G, Moran K, Craft D. Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility. Clin Infect Dis. 2005;41:758-759.10.1086/43262316080102
  22. 22. Ikonomidis A, Pournaras S, Maniatis AN, Legakis NJ, Tsakris A. Discordance of meropenem versus imipenem activity against Acinetobacter baumannii. Int J Antimicrob Agents. 2015;28:376-377.10.1016/j.ijantimicag.2006.07.007
  23. 23. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother. 2005;49:1337-1339.10.1128/AAC.49.4.1337-1339.2005
  24. 24. Wood GC, Hanes SD, Croce M a, Fabian TC, Boucher B a. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002;34:1425-1430.10.1086/340055
  25. 25. Yang Q, Zhang H, Cheng J, et al. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China. Int J Antimicrob Agents. 2015;45:485-490.10.1016/j.ijantimicag.2014.11.012
  26. 26. Kanayama A, Kobayashi I, Shibuya K. Distribution and antimicrobial susceptibility profile of extended-spectrum β-lactamase-producing Proteus mirabilis strains recently isolated in Japan. Int J Antimicrob Agents. 2015;45:113-118.10.1016/j.ijantimicag.2014.06.005
  27. 27. Dzutsev A, Trinchieri G. Proteus mirabilis: The Enemy Within. Immunity. 2015;42:602-604.10.1016/j.immuni.2015.04.004
  28. 28. O’Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 2000;13:534-546.10.1128/CMR.13.4.534
  29. 29. Nijssen S, Florijn A, Bonten MJM, et al. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents. 2015;24:585-591.10.1016/j.ijantimicag.2004.08.008
  30. 30. De Champs C, Bonnet R, Sirot D, Chanal C, Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: a two year survey. J Antimicrob Chemother. 2000;45:537-539.10.1093/jac/45.4.537
  31. 31. Stürenburg E, Mack D. Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect. 2015;47:273-295. 10.1016/S0163-4453(03)00096-3
  32. 32. Hofmann A, Sommer R, Hauck D, et al. Synthesis of mannoheptose derivatives and their evaluation as inhibitors of the lectin LecB from the opportunistic pathogen Pseudomonas aeruginosa. Carbohydr Res. 2015;412:34-42.10.1016/j.carres.2015.04.010
  33. 33. Sahner JH, Empting M, Kamal A, et al. Exploring the chemical space of ureidothiophene-2-carboxylic acids as inhibitors of the quorum sensing enzyme PqsD from Pseudomonas aeruginosa. Eur J Med Chem. 2015;96:14-21.10.1016/j.ejmech.2015.04.007
  34. 34. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. Int J Antimicrob Agents. 2015;45:568-585.10.1016/j.ijantimicag.2015.03.001
  35. 35. Michalopoulos a. S, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115-121.10.1111/j.1469-0691.2004.01043.x
  36. 36. Frédéric G, Julien T, Benoit R, et al. Selective digestive decontamination and empirical antimicrobial therapy of late - Onset ventilator - Associated pneumonia in trauma patients. J Acute Dis. 2012;1:1-6.10.1016/S2221-6189(13)60001-3
  37. 37. Cohen MJ, Block CS, Moses AE, Nir-Paz R. Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance. Clin Microbiol Infect. 2014;20:O188-196.10.1111/1469-0691.12362
  38. 38. Van der Wolf PJ, Rothkamp A, Junker K, de Neeling AJ. Staphylococcus aureus (MSSA) and MRSA (CC398) isolated from post-mortem samples from pigs. Vet Microbiol. 2012;158(1-2):136-141.10.1016/j.vetmic.2012.01.025
  39. 39. Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect. 2011;17:1581-1586.
  40. 40. Patel H, Nguyen GC. S1103 Association of Methicillin-Resistant Staph Aureus (MRSA) with Higher Mortality Among Hospitalized IBD Patients. Gastroenterology. 2009;136:A - 189.10.1016/S0016-5085(09)60852-0
  41. 41. Köck R, Winner K, Schaumburg F, et al. Admission prevalence and acquisition of nasal carriage of meticillin-resistant Staphylococcus aureus (MRSA) in German rehabilitation centres. J Hosp Infect. 2014;87:115-118.10.1016/j.jhin.2014.02.00724792577
  42. 42. González-Domínguez M, Seral C, Sáenz Y, et al. Epidemiological features, resistance genes, and clones among community-onset methicillinresistant Staphylococcus aureus (CO-MRSA) isolates detected in northern Spain. Int J Med Microbiol. 2012;302:320-326.10.1016/j.ijmm.2012.10.00323177275
  43. 43. Goodwin KD, McNay M, Cao Y, et al. A multi-beach study of Staphylococcus aureus, MRSA, and enterococci in seawater and beach sand. Water Res. 2012;46:4195-4207.10.1016/j.watres.2012.04.001
  44. 44. Rao N, Bennett JE. Eradication of methicillin resistant Staph aureus (MRSA) with ciprofloxacin. Am J Infect Control. 1989;17:117.10.1016/0196-6553(89)90116-8
  45. 45. Chang Y-Y, Chuang Y-C, Siu LK, et al. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan. J Microbiol Immunol Infect. 2015;48:219-225.10.1016/j.jmii.2014.05.01025074627
  46. 46. Jana M, Misra AK. Synthesis of trisaccharide and a tetrasaccharide repeating unit corresponding to the O-antigen of Shiga toxin producing Escherichia coli O177. Tetrahedron. 2015;71:3960-3965.10.1016/j.tet.2015.04.042
  47. 47. Magdy A, Elhadidy M, Abd Ellatif ME, et al. Enteropathogenic Escherichia coli (EPEC): Does it have a role in colorectal tumourigenesis? A Prospective Cohort Study. Int J Surg. 2015;18:169-173.10.1016/j.ijsu.2015.04.07725937151
  48. 48. Perepelov A V, Wang Q, Senchenkova SN, et al. Structure and gene cluster of the O-antigen of Escherichia coli O140. Carbohydr Res. 2015;411:33-36.10.1016/j.carres.2015.04.00425965146
  49. 49. Zdorovenko EL, Golomidova AK, Prokhorov NS, et al. Structure of the O-polysaccharide of Escherichia coli O87. Carbohydr Res. 2015;412:15-18.10.1016/j.carres.2015.04.01425988496
  50. 50. Giakkoupi P, Tryfinopoulou K, Polemis M, et al. Circulation of a multiresistant, conjugative, IncA/C plasmid within the nosocomial Providencia stuartii population in the Athens area. Diagn Microbiol Infect Dis. 2015;82:62-64.10.1016/j.diagmicrobio.2015.02.00925752202
  51. 51. Mahrouki S, Chihi H, Bourouis A, et al. Nosocomial dissemination of plasmids carrying blaTEM-24, blaDHA-1, aac(6’)-Ib-cr, and qnrA6 in Providencia spp. strains isolated from a Tunisian hospital. Diagn Microbiol Infect Dis. 2015;81:50-52.10.1016/j.diagmicrobio.2014.09.02125315769
  52. 52. Ovchinnikova OG, Moryl M, Shashkov AS, Chizhov AO, et al. Structure of the O-polysaccharide of Providencia alcalifaciens O2 containing ascarylose and N-(L-alanyl)-D-glucosamine. Carbohydr Res. 2015;401:11-15.10.1016/j.carres.2014.10.01625464076
  53. 53. Luzzaro F, Mezzatesta M, Mugnaioli C, et al. Trends in production of extended-spectrum - β-lactamases among enterobacteria of medical interest: Report of the second Italian nationwide survey. J Clin Microbiol. 2006;44:1659-1664. 10.1128/JCM.44.5.1659-1664.2006147920716672390
DOI: https://doi.org/10.1515/amma-2016-0001 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 21 - 26
Submitted on: Oct 30, 2015
|
Accepted on: Jan 5, 2016
|
Published on: Feb 9, 2016
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2016 Ovidiu Horea Bedreag, Alexandru Florin Rogobete, Loredana Luca, Claudiu Neamtu, Dorian Mihai Dragulescu, Radu Nartita, Marius Papurica, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.